News

Spanish Zeltia bags milestone payment
Enlarge image

BusinessSpain

Spanish Zeltia bags milestone payment

27.04.2012 - Zeltia Group has received €19m from its partner Johnson & Johnson. Progress with the cancer drug Yondelis triggered the milestone payment.

Madrid – Zeltia’s oncology subsidiary PharmaMar S.A. has received a second €19m milestone payment from Yondelis (trabectedin) ex-Europe partner Janssen, a Johnson & Johnson company. This follows the December 2011 receipt of €19m paid on agreement of a new US development plan. In late December 2011, PharmaMar reached the agreement with J&J subsidiary Janssen to push forward the development of Yondelis (trabectedin) in the US, with studies using the anti-tumour drug for the treatment of recurrent ovarian cancer and L-sarcoma.

Under the terms of the agreement, PharmaMar received a first €19m milestone payment at the end of 2011. On top of the actual €19m payment further €60m of milestones may fall due in 2013/2015, in addition to the economics agreed at the time of the original license. The PharmaMar mother company is approaching additional key pipeline catalysts, with an interim analysis of the ADMYRE study of Aplidin in relapsed/refractory multiple myeloma expected soon. An interim analysis of the Phase II PM01183 trial in resistant ovarian cancer and results of a Phase II study of Nypta (tideglusib) in Alzheimer’s disease, are both due at the end of the year. Yondelis is already marketed for the treatment of advanced soft tissue sarcoma and ovarian cancer in Europe, Russia and South Korea. Yondelis sales growth to €80m (+12%) in 2011 was hampered by supply issues with Doxil, with which it is administered in ovarian cancer. However Yolendis sales declined in Q1/2012 compared to the first quarter in 2011.

http://www.european-biotechnology-news.com/news/news/2012-02/spanish-zeltia-bags-eur19m-milestone-payment.html

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

M&AIreland

31.03.2015 In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.

BusinessGermany

31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%

FLOP

  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%

TOP

  • MEDIGENE12.90 EUR93.4%
  • 4SC1.18 EUR66.2%
  • FORMYCON31.00 EUR37.7%

FLOP

  • CYTOS1.28 CHF-14.7%
  • MORPHOSYS60.74 EUR-12.8%
  • BB BIOTECH281.20 EUR-11.3%

TOP

  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%

FLOP

  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 17.04.2015